Azithromycin Prescribed Despite Risk for QTc Prolongation

This article originally appeared here.
Share this content:
Azithromycin Prescribed Despite Risk for QTc Prolongation
Azithromycin Prescribed Despite Risk for QTc Prolongation

TUESDAY, Jan. 12, 2016 (HealthDay News) -- Azithromycin is frequently prescribed to hospitalized patients despite the presence of risk factors for QTc prolongation, according to a study published in the January issue of the Journal of Hospital Medicine.

In a retrospective cohort study, Rachael A. Lee, M.D., from the University of Alabama at Birmingham, and colleagues examined inpatient prescribing patterns and risk factors for QTc elongation. Data were included for 100 inpatients aged 19 years or older who were randomly selected from 1,610 patient encounters and who were administered at least one dose of azithromycin.

The researchers found that 79 percent of azithromycin use was empiric. Overall, 65 percent of patients received a baseline electrocardiogram before azithromycin prescription; 60 percent of these patients had borderline or abnormal QTc prolongation. Seventy-six percent of patients were prescribed one or more QTc-prolonging medication in addition to azithromycin, most often ondansetron, trazodone, and moxifloxacin; 19 percent received three or more QTc medications in addition to azithromycin.

"In a cohort of hospitalized patients, azithromycin was prescribed despite risk factors for QTc prolongation and administration of interacting medications," the authors write. "Selection of azithromycin by providers appears to be independent from these risk factors, and education and vigilance to drug-drug interactions may be useful in limiting cardiac events with prescribing azithromycin."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »